Evidence map›Paper›PMID 40464929›Full record

ArticleWiener klinische Wochenschrift2025

Use of

Siroos Mirzaei, Gregor Schweighofer-Zwink, Heidemarie Ofner, Jasmin Bektic, Harun Fajkovic, Eisabeth von Guggenberg, Anton Ponholzer, Gero Kramer, Lukas Lusuardi, Michael Gabriel and 3 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Real-world outcomes of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. [Wiener klinische Wochenschrift · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Siroos MirzaeiDepartment of Nuclear Medicine with PET Center, Clinic Ottakring, Vienna, Austria.
Gregor Schweighofer-ZwinkDepartment of Nuclear Medicine and Endocrinology, Paracelsus Medical University Salzburg, Salzburg, Austria.
Heidemarie OfnerDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Jasmin BekticDepartment of Urology, Medical University of Innsbruck, Innsbruck, Austria.
Harun FajkovicDepartment of Urology, Medical University of St. Pölten, St. Pölten, Austria.
Eisabeth von GuggenbergDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Anton PonholzerDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Gero KramerDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Lukas LusuardiDepartment of Urology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
Michael GabrielNuclear Medicine and Endocrinology, Kepler University Hospital, Linz, Austria.
Tatjana Traub-WeidingerDepartment of Diagnostic and Therapeutic Nuclear Medicine, Clinic Donaustadt, Vienna Health Care Group, Vienna, Austria.
Marcus HackerDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Shahrokh F ShariatDepartment of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) remains a leading cause of cancer-related morbidity and mortality in men. Over the past decades, the incidence has risen in all age groups. Prostate-specific membrane antigen (PSMA)-based theranostics, which involve the use of PSMA-targeting radiopharmaceuticals for both diagnostic imaging and therapeutic applications, have become integral in the management of patients with metastatic castration-resistant prostate cancer (mCRPC). The field has witnessed a substantial and continuously expanding body of scientific literature, encompassing case reports, original research, systematic reviews and also clinical guidelines. The objective of this joint statement is to enhance awareness of PSMA theranostics and underscore their critical role in contemporary precision oncology. We aim to provide a comprehensive yet practical perspective on the current landscape of PSMA-based diagnostic and therapeutic modalities, offering a consensus-driven approach to their clinical application.

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IILutetiumProstatic Neoplasms, Castration-ResistantRadioisotopesRadiopharmaceuticalsTheranostic NanomedicineAustriaHumansMaleNuclear MedicineAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILutetiumLutetium-177RadioisotopesRadiopharmaceuticals177LU-PSMAProstate CancerRadioligand therapyTheranostic

Identifiers

PMID40464929
PMCPMC12137475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.